The company has also secured an additional $2 million optional financing commitment in this series. Panacea Pharmaceuticals chairman & CEO/CSO Hossein Ghanbari said: "Our lead drug candidate, our
G204 is a double-blind, placebo-controlled cumulative dose selection study for grass allergic rhinitis, which follows the successful completion of the GMM102 (G102) safety study, which demonstrated safety of
The OPTIC-2L (Optimizing Ponatinib Treatment In CML, Second Line) trial is designed to investigate the efficacy and safety of ponatinib, administered at two starting doses, compared with nilotinib,
KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein
Both products are formulated with aloe vera and Cortivera™ contains 0.5% hydrocortisone and Cortivera Plus™ contains 1% hydrocortisone. Both are available in cream and ointment form in order
Bial director of research & development department Patrício Soares-da-Silva said: "The study met its primary endpoint, which was the proportion of seizure-free patients for six consecutive months under
In the study, adult patients under 60 years of age with newly-diagnosed FLT3-mutated acute myeloid leukemia (AML) who received the investigational compound PKC412 (midostaurin) plus standard induction and
With this validation, the Radius application is complete and now under review by the EMA. Radius Health president and CEO Robert Ward said: "The MAA for abaloparatide-SC is
ADCT plans to initiate Phase I clinical trials in both NHL and ALL. ADCT-402 combines a humanized monoclonal antibody targeting CD19 with a pyrrolobenzodiazepine (PBD) warhead. In preclinical
Acorda executive director of device and program management Sean Plunkett said: "CVT-427 represents an innovative approach to acute treatment of migraines. Applying Acorda’s proprietary ARCUS technology, we have
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.